STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1619 by analyst upside · 2026-06-27
LBRX
LB Pharmaceuticals Inc
Healthcare · Market Cap $915M · P/E 0x
ANALYST PRICE TARGET
+41.0%
implied upside to consensus target
Current Price $31.92
Consensus Target $45.0
Bull Target $78.0
Bear Target $34.0
Analysts Covering 6
ANALYST CONSENSUS — BUY
Strong Buy
2
Buy
4
Hold
0
Sell
0
52-Week Low $13.36
52-Week High $33.47
YTD Return +56.2%
FUNDAMENTALS
Market Cap $915M
P/E Ratio (TTM) N/A
Forward P/E -7.1x
EPS (TTM) $-1.40
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $13.36
52-Week High $33.47
Current Price $31.92
Bear Target $34.0
Bull Target $78.0
● Now $31.92 ● Target $45.0
TRADING DATA
Avg Volume 238K
YTD Return +56.2%
Analyst Count 6
Consensus Buy
Upside to Target +41.0%
Last Updated 2026-06-27

ANALYST SUMMARY

LB Pharmaceuticals Inc (LBRX) is currently trading at $31.92 with a Wall Street consensus price target of $45.0, implying potential upside of 41.0% over the next 12 months. 6 analysts currently cover LBRX, with a consensus rating of Buy — 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $78.0, while the most cautious has a target of $34.0.

LBRX operates in the Healthcare sector with a market capitalisation of $915M. The stock is up 56.2% year-to-date and is currently trading near the upper end of its 52-week range of $13.36 – $33.47.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for LBRX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

HC Wainwright & Co. ● Initiated
Buy 2026-04-27 31% win rate (48 calls)
Craig-Hallum ● Initiated
Buy 2026-04-10 Building track record
Stifel — Reiterated
Buy → Buy 2026-03-27 Building track record
Stifel — Reiterated
Buy → Buy 2025-12-11 Building track record
Stifel ● Initiated
Buy 2025-10-06 Building track record
Piper Sandler ● Initiated
Overweight 2025-10-06 14% win rate (7 calls)
Leerink Partners ● Initiated
Outperform 2025-10-06 29% win rate (7 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
out of 100
Coverage depth
0/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
0/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →